Assessment of Eplerenone effects on the imaging findings in acute central serous chorioretinopathy: a randomized clinical trial
Phase 3
Recruiting
- Conditions
- Acute central serous chorioretinopathy.Central serous chorioretinopathy, unspecified eyeH35.719
- Registration Number
- IRCT20191116045458N1
- Lead Sponsor
- Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Patients that are referred to khatam eye hospital emergency room or clinics with the definite first episode of acute CSCR diagnosis with decreased visual acuity or metamorphopsia for less than 3 months
No history of intraocular diseases
No contraindication for eplerenone use (renal, heart or liver failure, pregnancy, breast feeding, K serum level more than 5 mg/dl, ACEI ,ARB or k-sparing diuretic use, hypertention,type 2 DM with microalbuminuria, use of azoles and clarithromycin).
Exclusion Criteria
any finding making CSCR diagnosis suspicious during treatment
detection of any intraocular disease during treatment
detection of any contraindication of Eplerenone during treatment
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Choroidal perfusion. Timepoint: Before starting treatment, 1 month later and 3 months later. Method of measurement: According to parameters including subfoveal choroidal thickness, vessel density and flow rate in superficial , deep and choriocapillary level in 3mm center of macula.
- Secondary Outcome Measures
Name Time Method Best corrected visual acuity. Timepoint: Before treatment starting, 1 month and 3 months later. Method of measurement: Examination by optometrist.;Central macula thickness. Timepoint: Before treatment starting, 1 month and 3 months later. Method of measurement: Performing OCT.;Subretinal fluid height. Timepoint: Before treatment starting, 1 month and 3 months later. Method of measurement: Performing OCT.;Optic nerve head perfusion. Timepoint: Before treatment starting, 1 month and 3 months later. Method of measurement: Vessel density flow index in OCT Angiography.